Results 81 to 90 of about 16,304 (256)

CT‐P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 Study

Allergy, EarlyView.
This study investigated the therapeutic equivalence of CT‐P39 (an omalizumab biosimilar) and EU‐approved reference omalizumab (ref‐OMA) in patients with chronic spontaneous urticaria. Therapeutic equivalence between CT‐P39 and ref‑OMA (300 mg) was demonstrated by the primary endpoint – confidence intervals of the treatment difference in mean change ...
Sarbjit S. Saini, Marcus Maurer, Yevgeniya Dytyatkovska, Ewa Springer, Maria Ratkova, Borislava Krusheva, Chun Wook Park, Grazyna Pulka, Marta Chełmińska, Adam Reich, Sunghyun Kim, Keumyoung Ahn, Suyoung Kim, Sewon Lee, Jieun Ka, Jongho Kim, Clive Grattan   +16 more
wiley   +1 more source

Switching to Biosimilars in Inflammatory Rheumatic Conditions: Current Knowledge

European Medical Journal Rheumatology, 2018
Biosimilars are more affordable versions of previously approved biopharmaceuticals that are designed to reduce healthcare expenditure and increase patient access to this therapeutic class. To achieve their economic potential, many European countries have
Filipe C. Araújo, Joao Eurico Fonseca, Joao Goncalves   +2 more
doaj  

Pharmacogenetics of follicle‐stimulating hormone action in the male

Andrology, EarlyView.
Abstract Male factor infertility (MFI) is involved in half of the cases of couple infertility. The follicle‐stimulating hormone (FSH) therapy is considered efficient to improve semen parameters and pregnancy rate in patients with idiopathic MFI, following the lesson learned from hypogonadotropic hypogonadism.
Andrea Graziani, Giuseppe Grande, Raffele Scafa, Riccardo Selice, Andrea Garolla, Maria Santa Rocca, Cinzia Vinanzi, Alberto Ferlin   +7 more
wiley   +1 more source

Factors that Influence Healthcare Professionals' Intentions towards Biosimilars

INNOVATIONS in Pharmacy
Background: Physicians often prescribe original biologic products to patients who have not used them before and are reluctant to switch to biosimilars.
Mohammed Alqahtani, Ahmed Al-Jedai, Albert Wertheimer   +2 more
doaj   +1 more source

Comparative efficacy of intravitreal anti‐VEGF therapy for neovascular age‐related macular degeneration: A systematic review with network meta‐analysis

Acta Ophthalmologica, EarlyView.
Abstract The aim of this review was to evaluate the comparative efficacy of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy for neovascular AMD. We searched 12 literature databases for randomised clinical trials (RCT) on anti‐VEGF therapy for neovascular AMD and extracted data on: change from baseline to 12 months in best ...
Emilie T. S. Butler, Andreas Arnold‐Vangsted, Marianne G. Schou, Rodrigo Anguita, Jakob Bjerager, Enrico Borrelli, Lasse J. Cehofski, Lorenzo Ferro Desideri, Elon H. C. van Dijk, Carsten Faber, Jakob Grauslund, Javad N. Hajari, Josef Huemer, Oliver N. Klefter, Marie Krogh Nielsen, M. Cem Sabaner, Miklos Schneider, Yousif Subhi   +17 more
wiley   +1 more source

How to use luspatercept and erythropoiesis‐stimulating agents in low‐risk myelodysplastic syndrome

British Journal of Haematology, EarlyView.
Summary Anaemia is the most common cytopenia in myelodysplastic syndrome (MDS), significantly impacting quality of life and morbidity. Erythropoiesis‐stimulating agents (ESAs) are the first‐line treatment for anaemia in lower risk (LR)‐MDS. The European Medicines Agency (EMA) approved epoetin alpha for LR‐MDS‐related anaemia in 2017, based on evidence ...
Valeria Santini, Angela Consagra
wiley   +1 more source

Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilCapsule Summary

JAAD International, 2020
Background: As biosimilars have become available in various parts of the world, the International Psoriasis Council has reviewed aspects of their use.
Arnon D. Cohen, MD, MPH, PhD, Ronald Vender, MD, FRCPC, Luigi Naldi, MD, Robert E. Kalb, MD, Tiago Torres, MD, PhD, Murlidhar Rajagopalan, MD, Joelle van der Walt, PhD, Lluís Puig, MD (Hon), PhD, Helen S. Young, MB ChB, PhD, FRCP   +8 more
doaj  

An Overview of Biosimilars—Development, Quality, Regulatory Issues, and Management in Healthcare

Pharmaceuticals
Biological therapies have transformed high-burden treatments. As the patent and exclusivity period for biological medicines draws to a close, there is a possibility for the development and authorization of biosimilars.
Filipa Mascarenhas-Melo, Mariana Diaz, Maria Beatriz S. Gonçalves, Pedro Vieira, Victoria Bell, Sofia Viana, Sara Nunes, Ana Cláudia Paiva-Santos, Francisco Veiga   +8 more
doaj   +1 more source

The protein science of biosimilars [PDF]

, 2006
Martin K. Kuhlmann, Adrian Covic
openalex   +1 more source

Towards Personalised Therapy in Chronic Spontaneous Urticaria: Advancing From Endotype to Clinical Response

Clinical &Experimental Allergy, EarlyView.
Chronic spontaneous urticaria (CSU) is a debilitating skin disorder with significant impact upon quality of life. Current guidelines advocate stepwise treatment of standard dose antihistamines, high dose antihistamines, omalizumab and ciclosporin.
Katie Ridge, Rizwan Ahmad, Barry Moran, Cliona O'Farrelly, Jean Dunne, Conor M. Finlay, Alan D. Irvine, Niall Conlon   +7 more
wiley   +1 more source